Lactate dehydrogenase is a serum prognostic factor in clinically regional lymph node-positive prostate cancer

LEANDRO BLAS, MASAKI SHIOTA, SHIGETOMO YAMADA, KOSUKE IEIRI, SHOHEI NAGAKAWA, SHIGEHIRO TSUKAHARA, TAKASHI MATSUMOTO, EIJI KASHIWAGI, ARIO TAKEUCHI, JUNICHI INOKUCHI, KEN ICHIRO SHIGA, Akira Yokomizo, MASATOSHI ETO

Research output: Contribution to journalArticlepeer-review

Abstract

Background/Aim: Currently, there is no established prognostic serum parameter except PSA in clinically regional lymph node-positive prostate cancer. The aim of this study was to identify serum prognostic factors in clinically regional lymph node-positive prostate cancer. Patients and Methods: Patients diagnosed with regional lymph node-positive prostate cancer between 2008 and 2017 were included. The prognostic value of serum parameters for progression-free survival (PFS) and overall survival (OS) was investigated. Results: Univariate and multivariate analyses showed a statistically significant increased hazard risk for PFS and OS for men with lactate dehydrogenase (LDH) ≥230 IU/l at diagnosis. PFS at 5 years for patients with high and low LDH levels were 69.9% (95% CI=56.8-79.8%) and 18.9% (95% CI=1.23-53.2%), respectively (p=0.003). OS at 5 years for low and high LDH levels were 89.2% (95% CI=78.6-94.7%) and 46.3 (95% CI=11.2-76.2%), respectively (p=0.006). Conclusion: This study shows that LDH is an independent predictor of PFS and OS in patients with regional lymph node metastatic prostate cancer.

Original languageEnglish
Pages (from-to)3885-3889
Number of pages5
JournalAnticancer research
Volume41
Issue number8
DOIs
Publication statusPublished - Aug 2021

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Lactate dehydrogenase is a serum prognostic factor in clinically regional lymph node-positive prostate cancer'. Together they form a unique fingerprint.

Cite this